ClinicalTrials.gg
CompletedNCT02009163Updated Jun 14, 2021Results posted

Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder

A Phase 3 interventional study of Lisdexamfetamine dimesylate and Placebo in Binge Eating Disorder, sponsored by Shire. Completed at 53 sites in 5 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2021-06-14.

Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
418
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 122 studies in Binge-Eating Disorder with a site in United States — 19 open to participants now, 26 under way, 2 of them phase 3. Binge-Eating Disorder · United States.

Enrollment
7th of 112
418 · median 67
Started
2014
with 3 others
Phase 3
15 of 122
2 open now
Registered
35th of 122
by date
Lead sponsor
5 of 122
Shire

Among the 122 studies in Binge-Eating Disorder with a site in United States, this one is the 7th largest by enrollment of the 112 interventional ones that give a count, is one of 4 that started in 2014, is one of 15 in phase 3, and was the 35th registered.

Binge-Eating Disorder

233 studies on the registry are indexed under Binge-Eating Disorder; 52 are open to participants now.

Browse Binge-Eating Disorder studies →

Open to participants now

19 of the 122 studies in Binge-Eating Disorder with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 34 Binge-Eating Disorder studies recruiting now, 8 (24%) set no upper age limit and 23 (68%) stop at 75 or younger; 10 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 122 studies in Binge-Eating Disorder with a site in United States, or all of them as a file.
02

Study summary

To evaluate maintenance of efficacy based on time to relapse between SPD489 (50 or 70mg) and placebo, as measured by the number of binge days (defined as days during which at least 1 binge episode occurs) per week as assessed by clinical interview based on subject diary and Clinical Global Impression - Severity (CGI-S) scores for patients who responded to SPD489 by the end of the Open-label Treatment Phase.

03

Conditions studied

  • Binge Eating Disorder

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is between 18-55 years of age, inclusive.
  2. Subject meets the following criteria for a diagnosis of BED:

    • Recurrent episodes of binge eating. An episode of binge eating is characterized by both of the following: eating, in a discrete period of time (eg, within a 2-hour period) an amount of food that is definitely larger than most people would eat in a similar period of time under similar conditions, and a sense of lack of control over the eating (eg, a feeling that one cannot stop eating or control what or how much one is eating).
    • The binge eating episodes are associated with at least 3 of the following: eating much more rapidly than normal; eating until uncomfortably full; eating large amounts of food when not feeling physically hungry; eating alone because of being embarrassed by how much one is eating; feeling disgusted with oneself, depressed, or feeling very guilty after overeating.
    • Marked distress regarding binge eating.
    • The binge eating occurs, on average, at least 2 days a week for 6 months.
    • The episodes of binge eating do not occur exclusively during the course of bulimia nervosa or anorexia nervosa.
  3. Subject is consistently able to swallow a capsule.

Exclusion criteria

Exclusion Criteria:

  1. Subject has current diagnosis of bulimia nervosa or anorexia nervosa.
  2. Subject is receiving psychotherapy or weight loss support within the past 3 months.
  3. Subject has used psychostimulants to facilitate fasting or dieting within the past 6 months.
  4. Subject has known history of symptomatic cardiovascular disease, advanced arteriosclerosis, structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease.
  5. Subject has abnormal thyroid function.
  6. Subject initiated treatment with a lipid lowering medication within the past 3 months.
  7. Subject has a history of moderate or severe hypertension.
  8. Subject has a recent history (within the past 6 months) of suspected substance abuse or dependence disorder.
  9. Subject has glaucoma.
  10. Subject is female and pregnant or nursing.
  11. Subjects who have had bariatric surgery, lap bands, duodenal stents, or other procedures for weight loss.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
418 participants (actual)

Study arms

  • Experimental
    Lisdexamfetamine dimesylate

    Administer one capsule (50 or 70 mg) orally daily at approximately 7:00 AM.

    Drug: Lisdexamfetamine dimesylate

  • Placebo comparator
    Placebo

    Administer one capsule orally daily at approximately 7:00 AM.

    Other: Placebo

Interventions

  • SDP489 30, 50, or 70mg capsule once per day (open-label and double-blind periods)

    Also known as: SPD489, LDX

  • OtherPlacebo

    Placebo capsule once per day (double-blind period)

06

What researchers measure

Primary outcomes

  1. Time to Relapse From Date of Randomization to Endpoint of The Randomized-withdrawal Period

    Relapse status was assessed during the double-blind treatment phase and was defined as having 2 or more binge days per week for 2 consecutive weeks (14 consecutive days) prior to any visit and having an increase in Clinical Global Impressions-Severity (CGI-S) score of 2 or more points compared to the randomized-withdrawal baseline (date of relapse - date of randomization). Binge eating information was captured via a self-report paper diary. The binge diary captured the number of binges per day, total hours per day spent binging, type of binge (at mealtime or at another time other than mealtime), and a description of the binge (amounts and types of foods). Binge frequency was reviewed by the clinician with the subject to confirm reported binge episodes per day. The CGI-S was performed to rate the severity of a subject's condition using a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill).

    Time frame: Visit 21 (26 weeks after randomization [Week 38] or Early Termination)

Secondary outcomes

  1. Change From Randomized-Withdrawal Baseline in The Number of Binge- Eating Days Per Week During The Randomized-withdrawal Period

    A binge day was defined as days during which at least 1 binge episode occurred. As assessed by clinical interview based on subject binge diary. Binge eating information was captured via a self-report paper diary. The binge diary captured the number of binges per day, total hours per day spent binging, type of binge (at mealtime or at another time other than mealtime), and a description of the binge (amounts and types of foods). Binge frequency was reviewed by the clinician with the subject to confirm reported binge episodes per day. A negative change from Baseline indicates that binge-related behavior decreased. The randomized -withdrawal-baseline was defined as the weekly average number of binge days for the 14 days prior to the Randomization Visit (Visit 8).

    Time frame: Randomized--withdrawal baseline (Visit 8; 12 weeks after start of open- label treatment [Week 12]), Visit 21 (26 weeks after randomization [Week 38])

  2. Percent of Participants Within Each Category of The Clinical Global Impression-Severity of Illness (CGI-S) Scale at Endpoint of The Randomized-withdrawal Period

    The CGI-S permits a global evaluation of a subject's condition and severity of symptoms. The CGI-S was performed to rate the severity of a subject's condition based on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill).

    Time frame: Visit 21 (26 weeks after randomization [Week 38] or Early Termination)

  3. Change From Randomized-Withdrawal Baseline in The Total Score of The Yale-Brown Obsessive Compulsive Scale Modified for Binge Eating (Y-BOCS-BE) During The Randomized-withdrawal Period

    The Y-BOCS-BE measures the obsession of binge eating thoughts and compulsiveness of binge eating behaviors. The scale is a clinician rated, 10-item scale, each item rated from 0 (no symptoms) to 4 (extreme symptoms). The scale includes questions regarding the amount of time spent on obsessions, impairment or distress experienced, and resistance and control over these thoughts. The same types of questions were asked about compulsions (ie, time spent, interference, etc.).Total scores range from 0 to 40. A total score of 0-7 is sub-clinical, 8-15 is mild, 16-23 is moderate, 24-31 is severe, and 32-40 is extreme. A decrease from baseline in Y-BOCS-BE Total Score represents an improvement in obsession with binge-eating thoughts or compulsiveness of binge-eating behaviors.

    Time frame: Randomized-withdrawal baseline (Visit 8; 12 weeks after start of open-label treatment [Week 12]), Visit 21 (26 weeks after randomization [Week 38])

  4. Percent of Participants Within Each Category of The EuroQuol Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) For Mobility at Endpoint of The Open-label Period

    The EuroQoL Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) is a health-related quality of life (QoL) measure that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression as well as current overall health. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses, from poor health to good health.

    Time frame: Visit 8 (12 weeks after start of open-label treatment [Week 12] or Early Termination)

  5. Percent of Participants Within Each Category of The EuroQuol Group 5--Dimension 5--Level Self--Report Questionnaire (EQ--5D--5L) For Mobility at Endpoint of The Randomized-withdrawal Period

    The EuroQoL Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) is a health-related quality of life (QoL) measure that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression as well as current overall health. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses, from poor health to good health.

    Time frame: Visit 21 (26 weeks after randomization [Week 38] or Early Termination)

  6. Percent of Participants Within Each Category of The EuroQuol Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) For Self Care at Endpoint of The Open-label Period

    The EuroQoL Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) is a health-related quality of life (QoL) measure that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression as well as current overall health. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses, from poor health to good health.

    Time frame: Visit 8 (12 weeks after start of open-label treatment [Week 12] or Early Termination)

  7. Percent of Participants Within Each Category of The EuroQuol Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) For Self Care at Endpoint of The Randomized-withdrawal Period

    The EuroQoL Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) is a health-related quality of life (QoL) measure that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression as well as current overall health. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses, from poor health to good health.

    Time frame: Visit 21 (26 weeks after randomization [Week 38] or Early Termination)

  8. Percent of Participants Within Each Category of The EuroQuol Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) For Usual Activities at Endpoint of The Open-label Period

    The EuroQoL Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) is a health-related quality of life (QoL) measure that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression as well as current overall health. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses, from poor health to good health.

    Time frame: Visit 8 (12 weeks after start of open-label treatment [Week 12] or Early Termination)

  9. Percent of Participants Within Each Category of The EuroQuol Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) For Usual Activities at Endpoint of The Randomized-withdrawal Period

    The EuroQoL Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) is a health-related quality of life (QoL) measure that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression as well as current overall health. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses, from poor health to good health.

    Time frame: Visit 21 (26 weeks after randomization [Week 38] or Early Termination)

  10. Percent of Participants Within Each Category of The EuroQuol Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) For Pain and Discomfort at Endpoint of The Open-label Period

    The EuroQoL Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) is a health-related quality of life (QoL) measure that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression as well as current overall health. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses, from poor health to good health.

    Time frame: Visit 8 (12 weeks after start of open-label treatment [Week 12] or Early Termination)

  11. Percent of Participants Within Each Category of The EuroQuol Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) For Pain and Discomfort at Endpoint of The Randomized-withdrawal Period

    The EuroQoL Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) is a health-related quality of life (QoL) measure that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression as well as current overall health. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses, from poor health to good health.

    Time frame: Visit 21 (26 weeks after randomization [Week 38] or Early Termination)

  12. Percent of Participants Within Each Category of The EuroQuol Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) For Anxiety And Depression at Endpoint of The Open-label Period

    The EuroQoL Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) is a health-related quality of life (QoL) measure that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression as well as current overall health. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses, from poor health to good health.

    Time frame: Visit 8 (12 weeks after start of open-label treatment [Week 12] or Early Termination)

  13. Percent of Participants Within Each Category of The EuroQuol Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) For Anxiety And Depression at Endpoint of The Randomized-withdrawal Period

    The EuroQoL Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) is a health-related quality of life (QoL) measure that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression as well as current overall health. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses, from poor health to good health.

    Time frame: Visit 21 (26 weeks after randomization [Week 38] or Early Termination)

  14. Number of Participants With a Positive Response on The Columbia Suicide Severity Rating Scale (C-SSRS) at Endpoint of The Open-label Period

    The C-SSRS is a semistructured interview that captures the occurrence, severity, and frequency of suicide-related thoughts and behaviors. The interview includes definitions and suggested questions to solicit the type of information needed to determine if a suicide-related thought or behaviour occurred. The interview was initiated with 5 (yes/no) questions, presented in ascending order of severity, about suicidal ideation. The most severe type of ideation was rated for frequency, duration, controllability, deterrents, and reason. If the answer to the first 2 ideation questions was "yes," the clinician asked questions 3-5. Active suicidal ideation included any participant who answered "yes" to questions 2-5. If the answers to ideation questions 1 and 2 were "No," then the clinician proceeded to 5 (yes/no) questions that addressed suicidal behavior, which was categorized as actual attempt, interrupted attempt, aborted attempt, preparatory acts or behaviors, and completed suicide.

    Time frame: Visit 8 (12 weeks after start of open-label treatment [Week 12])

  15. Number of Participants With a Positive Response on The Columbia Suicide Severity Rating Scale (C-SSRS) at Endpoint of The Randomized-withdrawal Period

    The C-SSRS is a semistructured interview that captures the occurrence, severity, and frequency of suicide-related thoughts and behaviors. The interview includes definitions and suggested questions to solicit the type of information needed to determine if a suicide-related thought or behaviour occurred. The interview was initiated with 5 (yes/no) questions, presented in ascending order of severity, about suicidal ideation. The most severe type of ideation was rated for frequency, duration, controllability, deterrents, and reason. If the answer to the first 2 ideation questions was "yes," the clinician asked questions 3-5. Active suicidal ideation included any participant who answered "yes" to questions 2-5. If the answers to ideation questions 1 and 2 were "No," then the clinician proceeded to 5 (yes/no) questions that addressed suicidal behavior, which was categorized as actual attempt, interrupted attempt, aborted attempt, preparatory acts or behaviors, and completed suicide.

    Time frame: Visit 21 (26 weeks after randomization [Week 38] or Early Termination)

  16. Total Scores For The Amphetamine Cessation Symptom Assessment (ACSA) Scale During Follow-up

    The ACSA was used in this study to assess potential withdrawal symptoms associated with chronic use of SPD489. The ACSA is a self-completed scale used to assess withdrawal symptoms. The scale has 16 symptom items rated on a 5-point scale ranging from 0 (not at all) to 4 (extremely). The ACSA total score ranges from 0-64, where a higher score indicates greater withdrawal symptom severity.

    Time frame: Visit 21 (26 weeks after randomization [Week 38] or Early Termination) and Visit 22 (7 days post last dose)

07

Results

Posted Apr 1, 2016

Participant flow

Open-label Period (Non-randomized)
Participant flow — Open-label Period (Non-randomized)
MilestoneSPD489 (Open-label Period)Placebo (Randomized-withdrawal Period)SPD489 (Randomized-withdrawal Period)
Started41800
Completed27500
Not completed14300
Withdrew: Failure to meet randomization criteria4800
Withdrew: Withdrawal by subject2900
Withdrew: Adverse event2200
Withdrew: Lost to follow-up2000
Withdrew: Protocol violation1000
Withdrew: Pregnancy100
Withdrew: Other1300
Randomized-withdrawal Period
Participant flow — Randomized-withdrawal Period
MilestoneSPD489 (Open-label Period)Placebo (Randomized-withdrawal Period)SPD489 (Randomized-withdrawal Period)
Started0138137
Completed050102
Not completed08835
Withdrew: Withdrawal by subject0259
Withdrew: Lost to follow-up0136
Withdrew: Adverse event006
Withdrew: Relapse criteria met0405
Withdrew: Protocol violation012
Withdrew: Pregnancy002
Withdrew: Other095

Outcome measures

PrimaryTime to Relapse From Date of Randomization to Endpoint of The Randomized-withdrawal Period

Relapse status was assessed during the double-blind treatment phase and was defined as having 2 or more binge days per week for 2 consecutive weeks (14 consecutive days) prior to any visit and having an increase in Clinical Global Impressions-Severity (CGI-S) score of 2 or more points compared to the randomized-withdrawal baseline (date of relapse - date of randomization). Binge eating information was captured via a self-report paper diary. The binge diary captured the number of binges per day, total hours per day spent binging, type of binge (at mealtime or at another time other than mealtime), and a description of the binge (amounts and types of foods). Binge frequency was reviewed by the clinician with the subject to confirm reported binge episodes per day. The CGI-S was performed to rate the severity of a subject's condition using a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill).

Time frame:
Visit 21 (26 weeks after randomization [Week 38] or Early Termination)
Reported as:
Median · days
Time to Relapse From Date of Randomization to Endpoint of The Randomized-withdrawal Period
daysPlacebo (Randomized-withdrawal Period)SPD489 (Randomized-withdrawal Period)
Time to Relapse From Date of Randomization to Endpoint of The Randomized-withdrawal PeriodNA (55.0 to NA)NA (NA to NA)
Statistical analysis
  • Placebo (Randomized-withdrawal Period) vs SPD489 (Randomized-withdrawal Period) · Log Rank · p = <0.001 (P-value based on a log-rank test, stratified by 4-week cessation status (Yes, No). 4-week cessation was defined as a subject having no binge days during the 4 weeks prior to randomization.)
SecondaryChange From Randomized-Withdrawal Baseline in The Number of Binge- Eating Days Per Week During The Randomized-withdrawal Period

A binge day was defined as days during which at least 1 binge episode occurred. As assessed by clinical interview based on subject binge diary. Binge eating information was captured via a self-report paper diary. The binge diary captured the number of binges per day, total hours per day spent binging, type of binge (at mealtime or at another time other than mealtime), and a description of the binge (amounts and types of foods). Binge frequency was reviewed by the clinician with the subject to confirm reported binge episodes per day. A negative change from Baseline indicates that binge-related behavior decreased. The randomized -withdrawal-baseline was defined as the weekly average number of binge days for the 14 days prior to the Randomization Visit (Visit 8).

Time frame:
Randomized--withdrawal baseline (Visit 8; 12 weeks after start of open- label treatment [Week 12]), Visit 21 (26 weeks after randomization [Week 38])
Reported as:
Least squares mean · days
Change From Randomized-Withdrawal Baseline in The Number of Binge- Eating Days Per Week During The Randomized-withdrawal Period
daysPlacebo (Randomized-withdrawal Period)SPD489 (Randomized--Withdrawal Period)
Change From Randomized-Withdrawal Baseline in The Number of Binge- Eating Days Per Week During The Randomized-withdrawal Period0.63 ± 0.0760.02 ± 0.061
Statistical analysis
  • Placebo (Randomized-withdrawal Period) vs SPD489 (Randomized--Withdrawal Period) · mixed- effects model for repeated measur · p = <0.001 (Nominal P-value not adjusted for multiplicity.) · Difference in ls mean: -0.61 · 95% CI -0.81 to -0.42MMRM over all post-randomization visits during the randomized-withdrawal phase. Value for change from baseline = outcome variable.
SecondaryPercent of Participants Within Each Category of The Clinical Global Impression-Severity of Illness (CGI-S) Scale at Endpoint of The Randomized-withdrawal Period

The CGI-S permits a global evaluation of a subject's condition and severity of symptoms. The CGI-S was performed to rate the severity of a subject's condition based on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill).

Time frame:
Visit 21 (26 weeks after randomization [Week 38] or Early Termination)
Reported as:
Number · percentage of participants
Percent of Participants Within Each Category of The Clinical Global Impression-Severity of Illness (CGI-S) Scale at Endpoint of The Randomized-withdrawal Period
percentage of participantsPlacebo (Randomized-withdrawal Period)SPD489 (Randomized-withdrawal Period)
Normal, Not at All Ill45.081.6
Borderline Mentally Ill10.711.8
Mildly Ill14.52.2
Moderately Ill22.12.2
Markedly Ill6.92.2
Severely Ill0.00.0
Among the Most Extremely Ill0.80.0
Statistical analysis
  • Placebo (Randomized-withdrawal Period) vs SPD489 (Randomized-withdrawal Period) · Cochran-Mantel-Haenszel · p = <0.001 (Unadjusted P-value for the difference in distribution between treatment groups in CGI-S.)Cochran-Mantel-Haenszel test with a modified ridit score, adjusting for Visit 8 (Week 12) CGI-S as the covariate.
SecondaryChange From Randomized-Withdrawal Baseline in The Total Score of The Yale-Brown Obsessive Compulsive Scale Modified for Binge Eating (Y-BOCS-BE) During The Randomized-withdrawal Period

The Y-BOCS-BE measures the obsession of binge eating thoughts and compulsiveness of binge eating behaviors. The scale is a clinician rated, 10-item scale, each item rated from 0 (no symptoms) to 4 (extreme symptoms). The scale includes questions regarding the amount of time spent on obsessions, impairment or distress experienced, and resistance and control over these thoughts. The same types of questions were asked about compulsions (ie, time spent, interference, etc.).Total scores range from 0 to 40. A total score of 0-7 is sub-clinical, 8-15 is mild, 16-23 is moderate, 24-31 is severe, and 32-40 is extreme. A decrease from baseline in Y-BOCS-BE Total Score represents an improvement in obsession with binge-eating thoughts or compulsiveness of binge-eating behaviors.

Time frame:
Randomized-withdrawal baseline (Visit 8; 12 weeks after start of open-label treatment [Week 12]), Visit 21 (26 weeks after randomization [Week 38])
Reported as:
Least squares mean · units on a scale
Change From Randomized-Withdrawal Baseline in The Total Score of The Yale-Brown Obsessive Compulsive Scale Modified for Binge Eating (Y-BOCS-BE) During The Randomized-withdrawal Period
units on a scalePlacebo (Randomized-withdrawal Period)SPD489 (Randomized-withdrawal Period)
Change From Randomized-Withdrawal Baseline in The Total Score of The Yale-Brown Obsessive Compulsive Scale Modified for Binge Eating (Y-BOCS-BE) During The Randomized-withdrawal Period5.5 ± 0.66-0.0 ± 0.52
Statistical analysis
  • Placebo (Randomized-withdrawal Period) vs SPD489 (Randomized-withdrawal Period) · mixed-effects model for repeated measure · p = <0.001 (Nominal P-value not adjusted for multiplicity.) · Difference in ls mean: -5.6 · 95% CI -7.2 to -3.9MMRM over all post-randomization visits during the randomized-withdrawal phase. Value for change from baseline = outcome variable.
SecondaryPercent of Participants Within Each Category of The EuroQuol Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) For Mobility at Endpoint of The Open-label Period

The EuroQoL Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) is a health-related quality of life (QoL) measure that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression as well as current overall health. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses, from poor health to good health.

Time frame:
Visit 8 (12 weeks after start of open-label treatment [Week 12] or Early Termination)
Reported as:
Number · percentage of participants
Percent of Participants Within Each Category of The EuroQuol Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) For Mobility at Endpoint of The Open-label Period
percentage of participantsOpen-label Safety Population
I have no problems in walking about87.9
I have slight problems in walking about9.8
Moderate problems in walking about1.5
I have severe problems in walking about0.8
I am unable to walk about0
SecondaryPercent of Participants Within Each Category of The EuroQuol Group 5--Dimension 5--Level Self--Report Questionnaire (EQ--5D--5L) For Mobility at Endpoint of The Randomized-withdrawal Period

The EuroQoL Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) is a health-related quality of life (QoL) measure that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression as well as current overall health. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses, from poor health to good health.

Time frame:
Visit 21 (26 weeks after randomization [Week 38] or Early Termination)
Reported as:
Number · percentage of participants
Percent of Participants Within Each Category of The EuroQuol Group 5--Dimension 5--Level Self--Report Questionnaire (EQ--5D--5L) For Mobility at Endpoint of The Randomized-withdrawal Period
percentage of participantsPlacebo (Randomized-withdrawal Period)SPD489 (Randomized-withdrawal Period)
I have no problems in walking about83.691.3
I have slight problems in walking about14.76.3
Moderate problems in walking about1.71.6
I have severe problems in walking about0.00.8
I am unable to walk about0.00.0
SecondaryPercent of Participants Within Each Category of The EuroQuol Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) For Self Care at Endpoint of The Open-label Period

The EuroQoL Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) is a health-related quality of life (QoL) measure that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression as well as current overall health. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses, from poor health to good health.

Time frame:
Visit 8 (12 weeks after start of open-label treatment [Week 12] or Early Termination)
Reported as:
Number · percentage of participants
Percent of Participants Within Each Category of The EuroQuol Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) For Self Care at Endpoint of The Open-label Period
percentage of participantsOpen-label Safety Population
I have no problems washing or dressing myself98.7
I have slight problems washing or dressing myself0.8
Moderate problems washing or dressing myself0.3
I have severe problems washing or dressing myself0.3
I am unable to wash or dress myself0
SecondaryPercent of Participants Within Each Category of The EuroQuol Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) For Self Care at Endpoint of The Randomized-withdrawal Period

The EuroQoL Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) is a health-related quality of life (QoL) measure that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression as well as current overall health. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses, from poor health to good health.

Time frame:
Visit 21 (26 weeks after randomization [Week 38] or Early Termination)
Reported as:
Number · percentage of participants
Percent of Participants Within Each Category of The EuroQuol Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) For Self Care at Endpoint of The Randomized-withdrawal Period
percentage of participantsPlacebo (Randomized-withdrawal Period)SPD489 (Randomized-withdrawal Period)
I have no problems washing or dressing myself98.398.4
I have slight problems washing or dressing myself0.90.8
Moderate problems washing or dressing myself0.90.8
I have severe problems washing or dressing myself0.00.0
I am unable to wash or dress myself0.00.0
SecondaryPercent of Participants Within Each Category of The EuroQuol Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) For Usual Activities at Endpoint of The Open-label Period

The EuroQoL Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) is a health-related quality of life (QoL) measure that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression as well as current overall health. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses, from poor health to good health.

Time frame:
Visit 8 (12 weeks after start of open-label treatment [Week 12] or Early Termination)
Reported as:
Number · percentage of participants
Percent of Participants Within Each Category of The EuroQuol Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) For Usual Activities at Endpoint of The Open-label Period
percentage of participantsOpen-label Safety Population
I have no problems doing my usual activities88.9
I have slight problems doing my usual activities8.1
Moderate problems doing my usual activities2.3
I have severe problems doing my usual activities0.8
I am unable to do my usual activities0
SecondaryPercent of Participants Within Each Category of The EuroQuol Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) For Usual Activities at Endpoint of The Randomized-withdrawal Period

The EuroQoL Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) is a health-related quality of life (QoL) measure that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression as well as current overall health. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses, from poor health to good health.

Time frame:
Visit 21 (26 weeks after randomization [Week 38] or Early Termination)
Reported as:
Number · percentage of participants
Percent of Participants Within Each Category of The EuroQuol Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) For Usual Activities at Endpoint of The Randomized-withdrawal Period
percentage of participantsPlacebo (Randomized-withdrawal Period)SPD489 (Randomized-withdrawal Period)
I have no problems doing my usual activities79.386.6
I have slight problems doing my usual activities16.411.0
Moderate problems doing my usual activities2.60.8
I have severe problems doing my usual activities0.01.6
I am unable to do my usual activities1.70.0
SecondaryPercent of Participants Within Each Category of The EuroQuol Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) For Pain and Discomfort at Endpoint of The Open-label Period

The EuroQoL Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) is a health-related quality of life (QoL) measure that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression as well as current overall health. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses, from poor health to good health.

Time frame:
Visit 8 (12 weeks after start of open-label treatment [Week 12] or Early Termination)
Reported as:
Number · percentage of participants
Percent of Participants Within Each Category of The EuroQuol Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) For Pain and Discomfort at Endpoint of The Open-label Period
percentage of participantsOpen-label Safety Population
I have no pain or discomfort72.3
I have slight pain or discomfort20.9
Moderate pain or discomfort5.3
I have severe pain or discomfort1.3
I have extreme pain or discomfort0.3
SecondaryPercent of Participants Within Each Category of The EuroQuol Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) For Pain and Discomfort at Endpoint of The Randomized-withdrawal Period

The EuroQoL Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) is a health-related quality of life (QoL) measure that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression as well as current overall health. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses, from poor health to good health.

Time frame:
Visit 21 (26 weeks after randomization [Week 38] or Early Termination)
Reported as:
Number · percentage of participants
Percent of Participants Within Each Category of The EuroQuol Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) For Pain and Discomfort at Endpoint of The Randomized-withdrawal Period
percentage of participantsPlacebo (Randomized-withdrawal Period)SPD489 (Randomized-withdrawal Period)
I have no pain or discomfort75.071.7
I have slight pain or discomfort16.418.1
Moderate pain or discomfort8.68.7
I have severe pain or discomfort0.00.0
I have extreme pain or discomfort0.01.6
SecondaryPercent of Participants Within Each Category of The EuroQuol Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) For Anxiety And Depression at Endpoint of The Open-label Period

The EuroQoL Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) is a health-related quality of life (QoL) measure that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression as well as current overall health. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses, from poor health to good health.

Time frame:
Visit 8 (12 weeks after start of open-label treatment [Week 12] or Early Termination)
Reported as:
Number · percentage of participants
Percent of Participants Within Each Category of The EuroQuol Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) For Anxiety And Depression at Endpoint of The Open-label Period
percentage of participantsOpen-label Safety Population
I am not anxious or depressed80.9
I am slightly anxious or depressed15.6
Moderately anxious or depressed2.3
I am severely anxious or depressed1.0
I am extremely anxious or depressed0.3
SecondaryPercent of Participants Within Each Category of The EuroQuol Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) For Anxiety And Depression at Endpoint of The Randomized-withdrawal Period

The EuroQoL Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) is a health-related quality of life (QoL) measure that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression as well as current overall health. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses, from poor health to good health.

Time frame:
Visit 21 (26 weeks after randomization [Week 38] or Early Termination)
Reported as:
Number · percentage of participants
Percent of Participants Within Each Category of The EuroQuol Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) For Anxiety And Depression at Endpoint of The Randomized-withdrawal Period
percentage of participantsPlacebo (Randomized-withdrawal Period)SPD489 (Randomized-withdrawal Period)
I am not anxious or depressed66.479.5
I am slightly anxious or depressed26.715.7
Moderately anxious or depressed4.33.1
I am severely anxious or depressed2.60.8
I am extremely anxious or depressed0.00.8
SecondaryNumber of Participants With a Positive Response on The Columbia Suicide Severity Rating Scale (C-SSRS) at Endpoint of The Open-label Period

The C-SSRS is a semistructured interview that captures the occurrence, severity, and frequency of suicide-related thoughts and behaviors. The interview includes definitions and suggested questions to solicit the type of information needed to determine if a suicide-related thought or behaviour occurred. The interview was initiated with 5 (yes/no) questions, presented in ascending order of severity, about suicidal ideation. The most severe type of ideation was rated for frequency, duration, controllability, deterrents, and reason. If the answer to the first 2 ideation questions was "yes," the clinician asked questions 3-5. Active suicidal ideation included any participant who answered "yes" to questions 2-5. If the answers to ideation questions 1 and 2 were "No," then the clinician proceeded to 5 (yes/no) questions that addressed suicidal behavior, which was categorized as actual attempt, interrupted attempt, aborted attempt, preparatory acts or behaviors, and completed suicide.

Time frame:
Visit 8 (12 weeks after start of open-label treatment [Week 12])
Reported as:
Number · participants
Number of Participants With a Positive Response on The Columbia Suicide Severity Rating Scale (C-SSRS) at Endpoint of The Open-label Period
participantsOpen-label Safety Population
Suicidal Behavior0
Active Suicidal Ideation0
Non-Suicidal Self-Injurious Behavior2
SecondaryNumber of Participants With a Positive Response on The Columbia Suicide Severity Rating Scale (C-SSRS) at Endpoint of The Randomized-withdrawal Period

The C-SSRS is a semistructured interview that captures the occurrence, severity, and frequency of suicide-related thoughts and behaviors. The interview includes definitions and suggested questions to solicit the type of information needed to determine if a suicide-related thought or behaviour occurred. The interview was initiated with 5 (yes/no) questions, presented in ascending order of severity, about suicidal ideation. The most severe type of ideation was rated for frequency, duration, controllability, deterrents, and reason. If the answer to the first 2 ideation questions was "yes," the clinician asked questions 3-5. Active suicidal ideation included any participant who answered "yes" to questions 2-5. If the answers to ideation questions 1 and 2 were "No," then the clinician proceeded to 5 (yes/no) questions that addressed suicidal behavior, which was categorized as actual attempt, interrupted attempt, aborted attempt, preparatory acts or behaviors, and completed suicide.

Time frame:
Visit 21 (26 weeks after randomization [Week 38] or Early Termination)
Reported as:
Number · participants
Number of Participants With a Positive Response on The Columbia Suicide Severity Rating Scale (C-SSRS) at Endpoint of The Randomized-withdrawal Period
participantsPlacebo (Randomized-withdrawal Period)SPD489 (Randomized-withdrawal Period)
Suicidal Behavior00
Active Suicidal Ideation00
Non-Suicidal Self-Injurious Behavior01
SecondaryTotal Scores For The Amphetamine Cessation Symptom Assessment (ACSA) Scale During Follow-up

The ACSA was used in this study to assess potential withdrawal symptoms associated with chronic use of SPD489. The ACSA is a self-completed scale used to assess withdrawal symptoms. The scale has 16 symptom items rated on a 5-point scale ranging from 0 (not at all) to 4 (extremely). The ACSA total score ranges from 0-64, where a higher score indicates greater withdrawal symptom severity.

Time frame:
Visit 21 (26 weeks after randomization [Week 38] or Early Termination) and Visit 22 (7 days post last dose)
Reported as:
Mean · units on a scale
Total Scores For The Amphetamine Cessation Symptom Assessment (ACSA) Scale During Follow-up
units on a scalePlacebo (Randomized-withdrawal Period)SPD489 (Randomized-withdrawal Period)
Visit 21, n=88, 947.6 ± 8.334.9 ± 7.81
Visit 22, n=75, 784.6 ± 5.845.3 ± 7.98

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SPD489 (Open-label Period)—3/411 (0.7%)303/411 (73.7%)
Placebo (Randomized-withdrawal Period)—0/134 (0%)45/134 (33.6%)
SPD489 (Randomized-withdrawal Period)—2/136 (1.5%)59/136 (43.4%)
Most frequent serious events
Most frequent serious events
EventSPD489 (Open-label Period)Placebo (Randomized-withdrawal Period)SPD489 (Randomized-withdrawal Period)
Nerve Root CompressionNervous system disorders0/4110/1341/136
Breast CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/4110/1341/136
Congenital Anomaly in OffspringCongenital, familial and genetic disorders1/4110/1340/136
PneumoniaInfections and infestations1/4110/1340/136
ConvulsionNervous system disorders1/4110/1340/136
Most frequent other events
Showing 10 of 34
Most frequent other events
EventSPD489 (Open-label Period)Placebo (Randomized-withdrawal Period)SPD489 (Randomized-withdrawal Period)
Dry mouthGastrointestinal disorders139/4112/1347/136
HeadacheNervous system disorders66/4119/13412/136
InsomniaPsychiatric disorders46/4112/1341/136
NasopharyngitisInfections and infestations20/4119/13413/136
Decreased appetiteMetabolism and nutrition disorders38/4110/1340/136
NauseaGastrointestinal disorders35/4113/1346/136
Upper respiratory tract infectionInfections and infestations11/4115/13411/136
AnxietyPsychiatric disorders29/4112/1342/136
ConstipationGastrointestinal disorders28/4111/1344/136
HyperhidrosisSkin and subcutaneous tissue disorders23/4110/1343/136

Baseline characteristics

The Open-label Safety Population (OSP) was defined as all participants who had taken at least 1 dose of SPD489 in the open-label period and who had a post-baseline safety assessment. Seven participants were enrolled but not treated and thus not included in the OSP.

Age, Continuous
Age, Continuous(years)Open-label Safety Population
Mean38.3 ± 10.40
Age, Customized
Age, Customized(Participants)Open-label Safety Population
< 40 years of age217
>/= 40 years of age194
Sex: Female, Male
Sex: Female, Male(Participants)Open-label Safety Population
Female358
Male53
08

Study locations

53 sites
  • Gulfcoast Clinical Research Center
    Fort Myers, Florida 33912, United States
  • Innovative Clinical Research, Inc
    Lauderhill, Florida 33319, United States
  • Compass Research LLC North Clinic
    Leesburg, Florida 34748, United States
  • Florida Clinical Research Center, LLC
    Maitland, Florida 32751, United States
  • Scientific Clinical Research, Inc
    North Miami, Florida 33161, United States
  • Clinical Neuroscience Solutions, Inc
    Orlando, Florida 32806, United States
  • Miami Research Associates
    South Miami, Florida 33143, United States
  • NeuroTrials Research, Inc
    Atlanta, Georgia 30342, United States
  • Capstone Clinical Research
    Libertyville, Illinois 60048, United States
  • Goldpoint Clinical Research
    Indianapolis, Indiana 46260, United States
  • Clinical Trials Technology, Inc
    Prairie Village, Kansas 66206, United States
  • Cypress Medical Research Center
    Wichita, Kansas 67226, United States
  • Louisiana Research Associates, Inc
    New Orleans, Louisiana 70114, United States
  • McLean Hospital
    Belmont, Massachusetts 02478, United States
  • Boston Clinical Trials
    Boston, Massachusetts 02131, United States
  • Adams Clinical Trials, LLC
    Watertown, Massachusetts 02472, United States
  • Rochester Center for Behavioral Medicine
    Rochester Hills, Michigan 48307, United States
  • HBSA-Pacific Institute for Research & Evaluation
    Albuquerque, New Mexico 87102, United States
  • Brooklyn Medical Institute
    Brooklyn, New York 11214, United States
  • Wake Research Associates, LLC
    Raleigh, North Carolina 27612, United States
  • Patient Priority Clinical Sites, LLC
    Cincinnati, Ohio 45215, United States
  • Community Research
    Cincinnati, Ohio 45227, United States
  • Midwest Clinical Research Center
    Dayton, Ohio 45417, United States
  • Linder Center of Hope
    Mason, Ohio 45040, United States
  • Oregon Center for Clinical Investigations, Inc (OCCI, Inc)
    Portland, Oregon 97214, United States
  • Oregon Center for Clinical Investigations, Inc (OCCI, Inc)
    Salem, Oregon 97301, United States
  • Lehigh Center for Clinical Research
    Allentown, Pennsylvania 18104, United States
  • Omega Medical Research
    Warwick, Rhode Island 02886, United States
  • Radiant Research, Inc
    Anderson, South Carolina 29621, United States
  • Radiant Research, Inc
    Greer, South Carolina 29650, United States
  • Coastal Carolina Research Center
    Mount Pleasant, South Carolina 29464, United States
  • Clinical Neuroscience Solution, Inc
    Memphis, Tennessee 38119, United States
  • FutureSearch Clinical Trials, LP
    Austin, Texas 78731, United States
  • FutureSearch Trials of Dallas, LP
    Dallas, Texas 75231, United States
  • Texas Center for Drug Development, Inc
    Houston, Texas 77081, United States
  • Research Across America
    Plano, Texas 75093, United States
  • Radiant Research, Inc
    San Antonio, Texas 78229, United States
  • Northwest Clinical Research Center
    Bellevue, Washington 98007, United States
  • Summit Research Network (Seattle) LLC
    Seattle, Washington 98104, United States
  • Anxiety and Mood Disorder Center
    Mississauga, Ontario L5< 4N4, Canada
  • Manna Research
    Pointe Claire, Quebec H9R 4S3, Canada
  • Klinische Forschung Berlin-Mitte GmbH
    Berlin, 10117, Germany
  • EMOVIS GmbH - Klinische Forschung
    Berlin, 10629, Germany
  • Klinische Forschung Dresden GmbH
    Dresden, 01069, Germany
  • Klinische Forschung Hannover-Mitte GmbH
    Hannover, 30159, Germany
  • Forschung Schwerin GmbH, Friedrichstrasse 1
    Schwerin, 19055, Germany
  • Studienzentrum Nordwest
    Westerstede, 26655, Germany
  • Hospital de la Santa Creu I Sant Pau
    Barcelona, 08025, Spain
  • Hospital Universitario Infanta Leonor
    Madrid, 28031, Spain
  • Hospital del Henares
    Madrid, 28822, Spain
  • Lakarmottagningen Ekdahl & Kronberg
    Malmo, 211 52, Sweden
  • Sofiahemmet
    Stockholm, 114 86, Sweden
  • Stockholm Center for Eating Disorders
    Stockholm, 118 50, Sweden
09

References and documents

Publications

  • Robertson B, Wu J, Fant RV, Schnoll SH, McElroy SL. Assessment of Amphetamine Withdrawal Symptoms of Lisdexamfetamine Dimesylate Treatment for Adults With Binge-Eating Disorder. Prim Care Companion CNS Disord. 2020 Mar 26;22(2):19m02540. doi: 10.4088/PCC.19m02540. PubMed 32237290 ↗
  • Hudson JI, McElroy SL, Ferreira-Cornwell MC, Radewonuk J, Gasior M. Efficacy of Lisdexamfetamine in Adults With Moderate to Severe Binge-Eating Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2017 Sep 1;74(9):903-910. doi: 10.1001/jamapsychiatry.2017.1889. PubMed 28700805 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2014 to primary completion in Apr 2015, 14 months.

Results were first posted in Apr 2016, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2013
First posted
Dec 11, 2013
StartActual
Jan 27, 2014
Primary completionActual
Apr 8, 2015
CompletionActual
Apr 8, 2015
Results first posted
Apr 1, 2016
Last update
Jun 14, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 14, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02009163
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Dec 11, 2013
Start date
Jan 27, 2014
Primary completion
Apr 8, 2015
Completion
Apr 8, 2015
Results posted
Apr 1, 2016
Last update
Jun 14, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lisdexamfetamine

Start the discussion